SAN MARINO, Calif., March 16 /PRNewswire/ -- Epeius Biotechnologies Corporation, an emerging leader in the field of targeted genetic medicine, received a notice of allowance from the USPTO for a crucial patent covering its leading tumor-targeted vaccine technology for cancer immunotherapy. The issuance of this valuable patent protection for tumor targeted immunotherapy follows on the heels of two international patents covering targeted gene medicine in the U.S. and Europe, respectively, and places Epeius Biotech at the forefront of these emerging fields of clinical medicine with best-of-breed solutions and incontrovertible proofs-of-principle in the clinic.
The advent of pathotropic (disease-seeking) targeting technology first enabled the development of tumor-targeted Rexin-G, which seeks-out, accumulates-in, and selectively delivers a lethal designer gene to tumors that have spread throughout the body (metastatic cancer), halting the progression of disease while improving both survival and quality-of-life. Approved for all solid tumors in the Philippines, Rexin-G has received Orphan Drug and Fast Track status from the U.S. FDA, and is currently moving on to Phase III trials for first-line and second-line indications. Once the control of tumor growth has been achieved with Rexin-G, the need to extend the treatment intervals and/or clinical remissions led to the development of Reximmune-C, a second tumor-targeted genetic medicine which delivers a pulse of immune-stimulating cytokine directly to the sites of residual or recurrent disease, thereby recruiting the patient's own immune system into the lesions of the residual cancer to invoke a more lasting anti-tumor immune response.
Much like a SWAT (special weapons and tactics) Team that calls an elite police force to the scene of a crime, Reximmune-C acts at the local level, recruiting the body's own professional immune cells, antigen-presenting cells, helper cells, and killer T-cells directly to the locus of the residual cancer, where tumor debris as antigens are abundant. This provides the patient with an opportunity to mount a beneficial immune response that would further improve clinical outcome. Unlike, previous approaches to personalized cancer vaccination, a simple intravenous infusion of tumor-targeted Reximmune-C marshals the cadre of complex immunological responses of this intrinsic SWAT Team to the place where it is needed most. By reaching beyond the boundaries of medicine to the very crux of metastatic disease, Epeius delivers another vital innovation.
About Epeius Biotechnologies:
Epeius Biotechnologies Corporation is a privately held biopharmaceutical company dedicated to the advancement of genetic medicine with the development and commercialization of its leading oncology products and its tumor-targeted delivery systems.
To learn more about our pipeline of proprietary biotechnologies, please visit us at http://www.epeiusbiotech.com .
*(LOGO 72dpi: Send2press.com/mediaboom/09-1012-EpeiusBio_72dpi.jpg)
This release was issued on behalf of the above organization by Send2Press(R), a unit of Neotrope(R). http://www.Send2Press.com
SOURCE Epeius BiotechnologiesBack to top
|SOURCE Epeius Biotechnologies|
Copyright©2010 PR Newswire.
All rights reserved